Zipalertinib

Zipalertinib (TAS6417/CLN-081) is an oral EGFR tyrosine kinase inhibitor built for EGFR exon 20 insertion NSCLC, a hard-to-drug subset where osimertinib and other standard EGFR drugs lose activity. The target is validated, not first-in-class: Janssen's amivantamab (Rybrevant, bispecific antibody, originally approved 2021 and now available as a 5-minute subcutaneous injection after FDA approval of Rybrevant Faspro in December 2024) and Dizal's sunvozertinib (Zegfrovy, oral TKI, FDA accelerated approval June 2, 2025) are already on market for this mutation. Taiho Oncology, Taiho Pharmaceutical, and co-developer Cullinan Therapeutics (CGEM) have reported that the Phase 3 REZILIENT3 trial (NCT05973773) met its primary endpoint of PFS by blinded independent central review (median 14.5 vs 8.5 months, HR 0.50, p<0.001) in first-line metastatic exon 20 insertion NSCLC, and rolling submission of a US NDA has been initiated. A second Phase 3, REZILIENT4 (NCT07128199), is active in the resected adjuvant setting [1][2][3][9][10][11][12].

Novel compound, not yet approved anywhere, but no longer early-stage: REZILIENT3 Phase 3 is a positive readout and NDA rolling submission is underway. Zipalertinib plus platinum-pemetrexed vs chemo alone showed median PFS 14.5 vs 8.5 months (HR 0.50, p<0.001) in first-line EGFR exon 20 insertion NSCLC, with a favorable brain metastases subgroup signal (HR 0.38) [10][11]. The REZILIENT1 Phase 1/2 package (NCT04036682, Piotrowska et al. JCO 2025) remains the pretreated-line evidence base, with confirmed ORR in the 35-40% range in platinum-pretreated patients including post-amivantamab activity, and a tolerable mostly on-target toxicity profile (rash, paronychia, GI) [1][3]. REZILIENT4 (NCT07128199) is actively recruiting in the resected adjuvant setting [4]. Cullinan has filed multiple 8-Ks in 2026 around the program, consistent with partnering, regulatory, or data communications [5].

EGFR is a cell-surface protein that signals cells to grow and divide. In lung cancer, EGFR mutations lock the switch in the 'on' position so the cell keeps dividing. The common EGFR mutations (exon 19 deletions, L858R) sit in positions that osimertinib and similar drugs bind easily. Exon 20 insertions are different: a short 1-7 amino acid insertion deforms the loop next to the ATP-binding pocket, changing the pocket shape just enough that standard EGFR drugs lose grip. Zipalertinib is designed with a geometry that fits the mutant pocket while largely sparing normal (wild-type) EGFR, which is the source of the severe skin and GI toxicity of older pan-EGFR drugs. The target is clinically validated: amivantamab is approved on this mutation, sunvozertinib was approved in June 2025, and mobocertinib was approved and then withdrawn in 2023 for failing its confirmatory trial. Le and colleagues' ZENITH poziotinib analysis showed that insertion sub-location (near-loop vs far-loop) predicts sensitivity, which matters for how a broad exon 20 label holds up across sub-mutations [7].

REZILIENT3 (NCT05973773) is a global, randomized, open-label Phase 3 testing zipalertinib 100 mg orally BID (in 21-day cycles) plus platinum-pemetrexed versus chemotherapy alone in previously untreated, locally advanced or metastatic nonsquamous NSCLC with EGFR exon 20 insertions. Primary endpoint is PFS by blinded independent central review per RECIST v1.1, with ~285 patients randomized 1:1 - a PFS primary that supports a full (not just accelerated) first-line approval if OS tracks [2][10]. REZILIENT4 (NCT07128199) is a randomized, double-blind Phase 3: patients with completely resected stage IB-IIIA NSCLC harboring uncommon EGFR mutations (including exon 20 insertions) are randomized to zipalertinib or placebo on top of standard adjuvant platinum chemotherapy. Primary endpoint is investigator-assessed disease-free survival, the standard adjuvant lung endpoint accepted by FDA, with target enrollment 360 [4]. REZILIENT4 is the longer-dated readout given DFS maturation in resected disease takes years. The REZILIENT1 Phase 1/2 (NCT04036682) at 100 mg BID remains the pretreated-line package [1][3].

Our model estimates a 17% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Competitive risk is now the dominant risk, not efficacy. Sunvozertinib (Zegfrovy) received FDA accelerated approval on June 2, 2025 for pretreated EGFR exon 20 insertion NSCLC and is pursuing first-line expansion - if sunvozertinib wins first-line label expansion before zipalertinib, zipalertinib could be relegated to second-line even with a positive REZILIENT3 [11][12]. Amivantamab plus lazertinib is also consolidating broader EGFR-mutant first-line share, and the December 2024 approval of subcutaneous Rybrevant Faspro (5-minute injection, administration-related reactions reduced from 66% IV to 13% SC) materially weakens the 'oral TKI vs toxic IV infusion' quality-of-life differentiator that zipalertinib was expected to lean on [11][13]. Efficacy risk in adjuvant setting (REZILIENT4): adjuvant DFS trials in resected lung cancer are hard; the uncommon EGFR mutation umbrella widens eligibility but may dilute signal if non-insertion mutations respond differently. Patient-selection risk: Le and colleagues showed with poziotinib that near-loop insertions respond and far-loop insertions do not, with roughly a 2-fold ORR gap. If zipalertinib has similar sub-selectivity, an all-comers label may underperform the biomarker-enriched Phase 2 ORR [7]. Resistance risk: the specific resistance landscape for exon 20 insertion-selective TKIs is still being characterized. Rare case-report-level evidence has described secondary mutations including T790M and C797S arising after exon 20 insertion TKI exposure, but these are not the established primary resistance mechanism and the generalizability to zipalertinib is unknown [8]. Safety: wild-type sparing is relative, not absolute; rash and GI already visible in Phase 2.

Status upgrade: this is no longer a 'watch for signal' asset. REZILIENT3 is a positive Phase 3 and the US NDA rolling submission is underway, so the next-named catalyst is a regulatory decision window (likely 2026-2027) rather than a data readout. The near-term equity story sits with Cullinan Therapeutics (CGEM) as the co-developer; Taiho carries global commercial infrastructure (parent company behind Lonsurf and Lytgobi). Cullinan has filed multiple 8-Ks in 2026, including 2026-10-02 [5] - those filings are the first place to look for FDA interaction updates, PDUFA assignment, and partnership economics. Cullinan's cash runway and the detailed royalty/profit-share terms with Taiho are the key questions for sizing the single-asset equity leverage and are not disclosed in the writeup inputs; check the most recent 10-Q. The ceiling here is not open-ended: amivantamab (now with SC Faspro reducing infusion burden) and sunvozertinib (oral, already approved for pretreated) are both competing for the same mutation. Zipalertinib's commercial case now hinges on label breadth (first-line plus post-chemo plus post-TKI), CNS activity (the brain metastases HR 0.38 signal is meaningful), and whether sunvozertinib's first-line expansion reads out before zipalertinib's approval.